Search

Your search keyword '"Wendland, Merideth M"' showing total 29 results
Start Over Author "Wendland, Merideth M"
29 results on '"Wendland, Merideth M"'

1. Independently validated sex-specific nomograms for predicting survival in patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825

Author

Patil, Nirav, Somasundaram, Eashwar, Waite, Kristin A., Lathia, Justin D., Machtay, Mitchell, Gilbert, Mark R., Connor, James R., Rubin, Joshua B., Berens, Michael E., Buerki, Robin A., Choi, Serah, Sloan, Andrew E., Penas-Prado, Marta, Ashby, Lynn S., Blumenthal, Deborah T., Werner-Wasik, Maria, Hunter, Grant K., Flickinger, John C., Wendland, Merideth M., Panet-Raymond, Valerie, Robins, H. Ian, Pugh, Stephanie L., Mehta, Minesh P., and Barnholtz-Sloan, Jill S.

Published
2021
Full Text
View/download PDF

2. Germline Polymorphisms in MGMT Associated With Temozolomide-Related Myelotoxicity Risk in Patients With Glioblastoma Treated on NRG Oncology/RTOG 0825

Author

Scheurer, Michael E, Zhou, Renke, Gilbert, Mark R, Bondy, Melissa L, Sulman, Erik P, Yuan, Ying, Liu, Yanhong, Vera, Elizabeth, Wendland, Merideth M, Youssef, Emad F, Stieber, Volker W, Komaki, Ritsuko R, Flickinger, John C, Kenyon, Lawrence C, Robins, H Ian, Hunter, Grant K, Crocker, Ian R, Chao, Samuel T, Pugh, Stephanie L, Armstrong, Terri S, Scheurer, Michael E, Zhou, Renke, Gilbert, Mark R, Bondy, Melissa L, Sulman, Erik P, Yuan, Ying, Liu, Yanhong, Vera, Elizabeth, Wendland, Merideth M, Youssef, Emad F, Stieber, Volker W, Komaki, Ritsuko R, Flickinger, John C, Kenyon, Lawrence C, Robins, H Ian, Hunter, Grant K, Crocker, Ian R, Chao, Samuel T, Pugh, Stephanie L, and Armstrong, Terri S

Abstract

Background: We sought to identify clinical and genetic predictors of temozolomide-related myelotoxicity among patients receiving therapy for glioblastoma. Methods: Patients (n = 591) receiving therapy on NRG Oncology/RTOG 0825 were included in the analysis. Cases were patients with severe myelotoxicity (grade 3 and higher leukopenia, neutropenia, and/or thrombocytopenia); controls were patients without such toxicity. A risk-prediction model was built and cross-validated by logistic regression using only clinical variables and extended using polymorphisms associated with myelotoxicity. Results: 23% of patients developed myelotoxicity (n = 134). This toxicity was first reported during the concurrent phase of therapy for 56 patients; 30 stopped treatment due to toxicity. Among those who continued therapy (n = 26), 11 experienced myelotoxicity again. The final multivariable clinical factor model included treatment arm, gender, and anticonvulsant status and had low prediction accuracy (area under the curve [AUC] = 0.672). The final extended risk prediction model including four polymorphisms in MGMT had better prediction (AUC = 0.827). Receiving combination chemotherapy (OR, 1.82; 95% CI, 1.02-3.27) and being female (OR, 4.45; 95% CI, 2.45-8.08) significantly increased myelotoxicity risk. For each additional minor allele in the polymorphisms, the risk increased by 64% (OR, 1.64; 95% CI, 1.43-1.89). Conclusions: Myelotoxicity during concurrent chemoradiation with temozolomide is an uncommon but serious event, often leading to treatment cessation. Successful prediction of toxicity may lead to more cost-effective individualized monitoring of at-risk subjects. The addition of genetic factors greatly enhanced our ability to predict toxicity among a group of similarly treated glioblastoma patients.

Published
2022

3. Germline polymorphisms in MGMT associated with temozolomide-related myelotoxicity risk in patients with glioblastoma treated on NRG Oncology/RTOG 0825

Author

Scheurer, Michael E, primary, Zhou, Renke, additional, Gilbert, Mark R, additional, Bondy, Melissa L, additional, Sulman, Erik P, additional, Yuan, Ying, additional, Liu, Yanhong, additional, Vera, Elizabeth, additional, Wendland, Merideth M, additional, Youssef, Emad F, additional, Stieber, Volker W, additional, Komaki, Ritsuko R, additional, Flickinger, John C, additional, Kenyon, Lawrence C, additional, Robins, H Ian, additional, Hunter, Grant K, additional, Crocker, Ian R, additional, Chao, Samuel T, additional, Pugh, Stephanie L, additional, and Armstrong, Terri S, additional

Published
2022
Full Text
View/download PDF

6. NRG/RTOG 1122: phase II double-blinded, placebo-controlled study of bevacizumab with/without trebananib in patients with recurrent glioblastoma or gliosarcoma

Author

Lee, Eudocia Q, Zhang, Peixin, Wen, Patrick Y, Gerstner, Elizabeth R, Reardon, David A, Aldape, Kenneth D, deGroot, John F, Pan, Edward, Raizer, Jeffrey J, Kim, Lyndon J, Chmura, Steven J, Robins, H Ian, Connelly, Jennifer M, Battiste, James D, Villano, John L, Wagle, Naveed, Merrell, Ryan T, Wendland, Merideth M, and Mehta, Minesh P

Subjects
Adult, Male, Recombinant Fusion Proteins, Gliosarcoma, Middle Aged, Article, Bevacizumab, Placebos, Treatment Outcome, Double-Blind Method, Antineoplastic Combined Chemotherapy Protocols, Humans, Female, Glioblastoma, Aged
Abstract

Targeting vascular endothelial growth factor (VEGF) alone does not improve overall survival (OS) in recurrent glioblastoma (rGBM). The angiopoiein (Ang)-TIE2 system may play a role in tumor survival under VEGF inhibition. We conducted a phase 2, double-blinded, placebo-controlled trial of bevacizumab plus trebananib (a novel Fc fusion protein that sequesters Ang1/Ang2) over bevacizumab alone in rGBM.Patients ≥18 years of age with a Karnofsky performance status ≥70 and GBM or variants in first or second relapse were randomized to bevacizumab 10 mg/kg every 2 weeks plus trebananib 15 mg/kg every week or bevacizumab plus placebo. The primary endpoint was 6-month progression-free survival (PFS).After an initial 6-patient lead-in cohort confirmed the safety of combining bevacizumab and trebananib, 115 eligible patients were randomized to the control (n = 58) or experimental treatment (n = 57). In the control arm, 6-month PFS was 41.1%, median survival time was 11.5 months (95% CI, 8.4-14.2 months), median PFS was 4.8 months (95% CI, 3.8-7.1 months), and radiographic response (RR) was 5.9%. In the experimental arm, 6-month PFS was 22.6%, median survival time was 7.5 months (95% CI, 6.8-10.1 months), median PFS was 4.2 months (95% CI, 3.7-5.6 months), and RR was 4.2%. The rate of severe toxicities was not significantly different between arms.The combination of bevacizumab and trebananib was well tolerated but did not significantly improve 6-month PFS rate, PFS, or OS for patients with rGBM over bevacizumab alone. The shorter PFS in the experimental arm with a hazard ratio of 1.51 (P = .04) suggests that the addition of trebananib to bevacizumab is detrimental.

Published
2020

8. Neurocognitive, symptom, and health-related quality of life outcomes of a randomized trial of bevacizumab for newly diagnosed glioblastoma (NRG/RTOG 0825)

Author

Wefel, Jeffrey S, primary, Armstrong, Terri S, additional, Pugh, Stephanie L, additional, Gilbert, Mark R, additional, Wendland, Merideth M, additional, Brachman, David G, additional, Roof, Kevin S, additional, Brown, Paul D, additional, Crocker, Ian R, additional, Robins, H Ian, additional, Hunter, Grant, additional, Won, Minhee, additional, and Mehta, Minesh P, additional

Published
2021
Full Text
View/download PDF

9. NRG/RTOG 1122: A phase 2, double‐blinded, placebo‐controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma

Author

Lee, Eudocia Q., primary, Zhang, Peixin, additional, Wen, Patrick Y., additional, Gerstner, Elizabeth R., additional, Reardon, David A., additional, Aldape, Kenneth D., additional, deGroot, John F., additional, Pan, Edward, additional, Raizer, Jeffrey J., additional, Kim, Lyndon J., additional, Chmura, Steven J., additional, Robins, H. Ian, additional, Connelly, Jennifer M., additional, Battiste, James D., additional, Villano, John L., additional, Wagle, Naveed, additional, Merrell, Ryan T., additional, Wendland, Merideth M., additional, and Mehta, Minesh P., additional

Published
2020
Full Text
View/download PDF

12. The association of health-related quality of life and cognitive function in patients receiving memantine for the prevention of cognitive dysfunction during whole-brain radiotherapy

Author

Laack, Nadia N, primary, Pugh, Stephanie L, additional, Brown, Paul D, additional, Fox, Sherry, additional, Wefel, Jeffrey S, additional, Meyers, Christina, additional, Choucair, Ali, additional, Khuntia, Deepak, additional, Suh, John H, additional, Roberge, David, additional, Wendland, Merideth M, additional, and Bruner, Deborah, additional

Published
2018
Full Text
View/download PDF

13. Influence of Residual Disease Following Surgical Resection in Newly Diagnosed Glioblastoma on Clinical, Neurocognitive, and Patient Reported Outcomes

Author

Hall, William A, primary, Pugh, Stephanie L, additional, Wefel, Jeffrey S, additional, Armstrong, Terri S, additional, Gilbert, Mark R, additional, Brachman, David G, additional, Werner-Wasik, Maria, additional, Wendland, Merideth M, additional, Brown, Paul D, additional, Chao, Samuel T, additional, Roof, Kevin S, additional, Robins, H Ian, additional, Mehta, Minesh P, additional, Curran, Walter J, additional, and Movsas, Benjamin, additional

Published
2018
Full Text
View/download PDF

14. Short delay in initiation of radiotherapy for patients with glioblastoma-effect of concurrent chemotherapy: a secondary analysis from the NRG Oncology/Radiation Therapy Oncology Group database

Author

Blumenthal, Deborah T, primary, Won, Minhee, additional, Mehta, Minesh P, additional, Gilbert, Mark R, additional, Brown, Paul D, additional, Bokstein, Felix, additional, Brachman, David G, additional, Werner-Wasik, Maria, additional, Hunter, Grant K, additional, Valeinis, Egils, additional, Hopkins, Kirsten, additional, Souhami, Luis, additional, Howard, Steven P, additional, Lieberman, Frank S, additional, Shrieve, Dennis C, additional, Wendland, Merideth M, additional, Robinson, Cliff G, additional, Zhang, Peixin, additional, and Corn, Benjamin W, additional

Published
2018
Full Text
View/download PDF

15. A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913

Author

Chinnaiyan, Prakash, primary, Won, Minhee, additional, Wen, Patrick Y, additional, Rojiani, Amyn M, additional, Werner-Wasik, Maria, additional, Shih, Helen A, additional, Ashby, Lynn S, additional, Michael Yu, Hsiang-Hsuan, additional, Stieber, Volker W, additional, Malone, Shawn C, additional, Fiveash, John B, additional, Mohile, Nimish A, additional, Ahluwalia, Manmeet S, additional, Wendland, Merideth M, additional, Stella, Philip J, additional, Kee, Andrew Y, additional, and Mehta, Minesh P, additional

Published
2017
Full Text
View/download PDF

16. The association of health-related quality of life and cognitive function in patients receiving memantine for the prevention of cognitive dysfunction during whole-brain radiotherapy.

Author

Laack, Nadia N, Pugh, Stephanie L, Brown, Paul D, Fox, Sherry, Wefel, Jeffrey S, Meyers, Christina, Choucair, Ali, Khuntia, Deepak, Suh, John H, Roberge, David, Wendland, Merideth M, and Bruner, Deborah

Subjects
QUALITY of life, COGNITIVE ability, COGNITIVE testing, STANDARDIZED tests, BRAIN metastasis, PET therapy
Abstract

Background This study evaluated the association between health-related quality of life (HRQOL) and cognition in patients receiving memantine for prevention of cognitive dysfunction during whole-brain radiotherapy (WBRT). Methods Adult patients with brain metastases received WBRT and were randomized to receive placebo or memantine, 20 mg per day, within 3 days of initiating radiotherapy, for 24 weeks. The Functional Assessment of Cancer Therapy-Brain module (FACT-Br) and Medical Outcomes Scale-Cognitive Functioning Scale (MOS-C) were completed in coordination with serial standardized tests of cognitive function. Results Of the 508 eligible patients, 442 (87%) consented to participate in the HRQOL portion and contributed to baseline analyses. Evaluable patients at 24 weeks (n = 246) included surviving patients completing FACT-Br, MOS-C, and objective cognitive assessments (n = 146, 59%) and patients alive at time of missed assessment (n = 100, 41%). Baseline cognitive function correlated significantly with FACT-Br and MOS-C self-reports. All domains of objective cognitive function showed declines over time. Neither FACT-Br nor MOS-C differed between the treatment arms. Emotional and functional well-being subscales of the FACT improved over time while the remainder of the FACT-Br domains remained stable. MOS-C scores declined over time. Conclusion Baseline cognitive function correlated significantly with FACT-Br and MOS-C scores. No by-arm differences in HRQOL were observed despite differences in objective cognitive function. Patient attrition and poor testing compliance remain significant problems in studies of cognitive function of brain metastases patients and further effort is needed to improve compliance with testing and sensitivity of patient-reported measures. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

18. Polymorphisms risk modeling for vascular toxicity in patients with glioblastoma treated on NRG Oncology/RTOG 0825.

Author

Zhou, Renke, primary, Scheurer, Michael E., additional, Gilbert, Mark R., additional, Bondy, Melissa, additional, Sulman, Erik P., additional, Yuan, Ying, additional, Liu, Yanhong, additional, Vera, Elizabeth, additional, Wendland, Merideth M, additional, Brachman, David, additional, Bearden, James, additional, McGovern, Susan Lynne, additional, Wilson, Steven S., additional, Judy, Kevin D., additional, Robins, H. Ian, additional, Hunter, Grant Kirton, additional, Pugh, Stephanie L, additional, and Armstrong, Terri S., additional

Published
2016
Full Text
View/download PDF

19. EPID-25GERMLINE POLYMORPHISMS IN MGMT INCREASE ABILITY TO MODEL TEMOZOLOMIDE (TMZ)-RELATED MYELOTOXICITY RISK IN PATIENTS WITH GLIOBLASTOMA (GBM) TREATED ON NRG ONCOLOGY/RTOG 0825

Author

Scheurer, Michael E., primary, Zhou, Renke, additional, Gilbert, Mark R., additional, Bondy, Melissa L., additional, Sulman, Erik P., additional, Yuan, Ying, additional, Liu, Yanhong, additional, Vera-Bolanos, Elizabeth, additional, Wendland, Merideth M., additional, Brachman, David G., additional, Stieber, Volker W., additional, Komaki, Ritsuko R., additional, Flickinger, John C., additional, Kenyon, Lawrence C., additional, Robins, H. Ian, additional, Hunter, Grant K., additional, Crocker, Ian R., additional, Chao, Samuel T., additional, Stella, Philip J., additional, Pugh, Stephanie L., additional, and Armstrong, Terri, additional

Published
2015
Full Text
View/download PDF

20. Comparative impact of treatment on patient reported outcomes (PROs) in patients with glioblastoma (GBM) enrolled in RTOG 0825.

Author

Armstrong, Terri S., primary, Won, Minhee, additional, Wefel, Jeffrey Scott, additional, Gilbert, Mark R., additional, Pugh, Stephanie L., additional, Brachman, David, additional, Komaki, Ritsuko, additional, Crocker, Ian R., additional, Robins, H. Ian, additional, Lee, R. Jeffrey, additional, Mehta, Minesh P., additional, and Wendland, Merideth M, additional

Published
2013
Full Text
View/download PDF

22. Neurocognitive function (NCF) outcomes in patients with glioblastoma (GBM) enrolled in RTOG 0825.

Author

Wefel, Jeffrey Scott, primary, Pugh, Stephanie L., additional, Armstrong, Terri S., additional, Gilbert, Mark R., additional, Won, Minhee, additional, Wendland, Merideth M, additional, Brachman, David, additional, Komaki, Ritsuko, additional, Crocker, Ian R., additional, Robins, H. Ian, additional, Lee, R. Jeffrey, additional, and Mehta, Minesh P., additional

Published
2013
Full Text
View/download PDF

24. The Impact of Involved Field Radiation Therapy in the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma With High-Dose Chemotherapy Followed by Hematopoietic Progenitor Cell Transplant

Author

Wendland, Merideth M. M., primary, Smith, David C., additional, Boucher, Kenneth M., additional, Asch, Julie D., additional, Pulsipher, Michael A., additional, Thomson, John W., additional, Shrieve, Dennis C., additional, and Gaffney, David K., additional

Published
2007
Full Text
View/download PDF

28. Clinical and Genetic Markers of Vascular Toxicity in Glioblastoma Patients: Insights from NRG Oncology RTOG-0825.

Author

Strauss JD, Gilbert MR, Mehta M, Li A, Ms RZ, Bondy ML, Sulman EP, Yuan Y, Liu Y, Vera E, Wendland MM, Stieber VW, Puduvalli VK, Choi S, Martinez NL, Robins HI, Hunter GK, Lin CF, Guedes VA, Richard MA, Pugh SL, Armstrong TS, and Scheurer ME

Abstract

Background: Glioblastoma (GBM) is an aggressive form of brain cancer in which treatment is associated with toxicities that can result in therapy discontinuation or death. This analysis investigated clinical and genetic markers of vascular toxicities in GBM patients during active treatment., Methods: 591 Non-Hispanic White GBM patients with clinical data were included in the analysis from NRG RTOG-0825. Genome-wide association studies (GWAS) were performed from genotyped blood samples (N=367) by occurrence of thrombosis or hypertension (grade ≥2). A clinical prediction model was produced for each vascular toxicity. Significant GWAS variants were then added to the clinical model as a single nucleotide polymorphism (SNP) -dose effect variable to produce the final genetic models., Results: Thrombosis and hypertension were experienced by 62 (11%) and 59 (10%) patients, respectively. Patients who experienced hypertension displayed improved survival over those without hypertension (median overall survival: 25.72 vs 15.47 months, p=0.002). The genetic model of thrombosis included corticosteroid use (OR: 7.13, p=0.02), absolute neutrophil count (OR: 1.008, p=0.19), body surface area (OR: 18.87, p=0.0008), and the SNP-dose effect (3 variants; OR: 3.79, p<.0001). The genetic model of hypertension included bevacizumab use (OR: 0.97, p=0.95) and the SNP-dose effect (6 variants; OR: 4.44, p<.0001)., Conclusion: In this study, germline variants were superior in predicting hypertension than clinical variables alone. Additionally, corticosteroid use was a considerable risk factor for thrombosis. Future investigations should confirm the hazard of corticosteroid use on thrombosis and the impact of bevacizumab in other malignancies after accounting for the genetic risk of hypertension., (© The Author(s) 2024. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.)

Published
2024
Full Text
View/download PDF

29. A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913.

Author

Chinnaiyan P, Won M, Wen PY, Rojiani AM, Werner-Wasik M, Shih HA, Ashby LS, Michael Yu HH, Stieber VW, Malone SC, Fiveash JB, Mohile NA, Ahluwalia MS, Wendland MM, Stella PJ, Kee AY, and Mehta MP

Subjects
Adolescent, Adult, Aged, Brain Neoplasms pathology, Dacarbazine administration & dosage, Everolimus administration & dosage, Female, Follow-Up Studies, Glioblastoma pathology, Humans, Male, Middle Aged, Prognosis, Survival Rate, Temozolomide administration & dosage, Young Adult, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Brain Neoplasms therapy, Chemoradiotherapy mortality, Glioblastoma therapy
Abstract

Background: This phase II study was designed to determine the efficacy of the mammalian target of rapamycin (mTOR) inhibitor everolimus administered daily with conventional radiation therapy and chemotherapy in patients with newly diagnosed glioblastoma., Methods: Patients were randomized to radiation therapy with concurrent and adjuvant temozolomide with or without daily everolimus (10 mg). The primary endpoint was progression-free survival (PFS) and the secondary endpoints were overall survival (OS) and treatment-related toxicities., Results: A total of 171 patients were randomized and deemed eligible for this study. Patients randomized to receive everolimus experienced a significant increase in both grade 4 toxicities, including lymphopenia and thrombocytopenia, and treatment-related deaths. There was no significant difference in PFS between patients randomized to everolimus compared with control (median PFS time: 8.2 vs 10.2 mo, respectively; P = 0.79). OS for patients randomized to receive everolimus was inferior to that for control patients (median survival time: 16.5 vs 21.2 mo, respectively; P = 0.008). A similar trend was observed in both O6-methylguanine-DNA-methyltransferase promoter hypermethylated and unmethylated tumors., Conclusion: Combining everolimus with conventional chemoradiation leads to increased treatment-related toxicities and does not improve PFS in patients with newly diagnosed glioblastoma. Although the median survival time in patients receiving everolimus was comparable to contemporary studies, it was inferior to the control in this randomized study.

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results